| Oct 30 |
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
|
| Sep 19 |
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
|
| Sep 12 |
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
|
| Sep 5 |
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 29 |
ProMIS Neurosciences files to sell 56.51M common shares for holders
|
| Aug 19 |
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
|
| Aug 9 |
ProMIS Neurosciences GAAP EPS of -$0.13
|
| Aug 8 |
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
|
| Aug 6 |
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
|
| Aug 1 |
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
|
